← Back to Search

Radiation Therapy

Quality-of-Life Assessment for Prostate Cancer

N/A

Waitlist Available

Led By Leslie Ballas

Research Sponsored by University of Southern California

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adenocarcinoma of the prostate treated primarily with radical prostatectomy

Any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 36 months after completion of sbrt

Awards & highlights

Study Summary

This trial is testing a new, higher dose of radiation therapy delivered over a shorter period of time to see if it is more effective with fewer side effects than the standard radiation therapy for patients with prostate cancer.

Eligible Conditions

Prostate Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 36 months after completion of sbrt

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 36 months after completion of sbrt

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 months after completion of sbrt for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose-per-fraction based on acute toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03

Secondary outcome measures

Incidence of adverse events assessed according to CTCAE v. 4.03

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (hypofractionated SBRT)Experimental Treatment3 Interventions

Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~780

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,638 Previous Clinical Trials

40,929,795 Total Patients Enrolled

561 Trials studying Prostate Cancer

507,171 Patients Enrolled for Prostate Cancer

University of Southern CaliforniaLead Sponsor

905 Previous Clinical Trials

1,596,576 Total Patients Enrolled

18 Trials studying Prostate Cancer

9,422 Patients Enrolled for Prostate Cancer

Leslie BallasPrincipal InvestigatorUniversity of Southern California

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available to participate in this experiment?

"This research project, which was initially published on May 12th 2015 and most recently updated on August 5th 2022, is no longer recruiting patients. Nevertheless, there are 1969 other medical trials actively enrolling individuals."

Answered by AI

Recent research and studies

International Journal of Radiation Oncology*Biology*PhysicsJournal

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy

Ballas, Leslie K., Chunqiao Luo, Eugene Chung, Amar U. Kishan, Igor Shuryak, David I. Quinn, Tanya Dorff, et al.. 2019. “Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy”. International Journal of Radiation Oncology*biology*physics. Elsevier BV. doi:10.1016/j.ijrobp.2018.12.047.

International Journal of Radiation Oncology*Biology*PhysicsJournal

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy

clinicaltrials.govStudy

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

2015. "Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02446366.